About: Anakinra for severe forms of COVID-19: a cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Anakinra for severe forms of COVID-19: a cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Anakinra for severe forms of COVID-19: a cohort study
Creator	Beaussier, Hélène Bézie, Yvonnick Chatellier, Gilles Dauriat, Gaëlle Emmerich, Joseph Hayem, Gilles Huet, Thomas Jouveshomme, Stéphane Laplanche, Sophie Lazareth, Isabelle Le Berre, Alice Le Pavec, Jérôme Mourad, Jean-Jacques Naccache, Jean-Marc Rheumatology, Sacco, Emmanuelle Salmeron, Sergio Voisin, Olivier Dauriat, G Le Pavec, J
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Coronaviruses can induce the production of interleukin (IL)-1β, IL-6, tumour necrosis factor, and other cytokines implicated in autoinflammatory disorders. It has been postulated that anakinra, a recombinant IL-1 receptor antagonist, might help to neutralise the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related hyperinflammatory state, which is considered to be one cause of acute respiratory distress among patients with COVID-19. We aimed to assess the off-label use of anakinra in patients who were admitted to hospital for severe forms of COVID-19 with symptoms indicative of worsening respiratory function. METHODS: The Ana-COVID study included a prospective cohort from Groupe Hospitalier Paris Saint-Joseph (Paris, France) and a historical control cohort retrospectively selected from the Groupe Hospitalier Paris Saint-Joseph COVID cohort, which began on March 18, 2020. Patients were included in the prospective cohort if they were aged 18 years or older and admitted to Groupe Hospitalier Paris Saint-Joseph with severe COVID-19-related bilateral pneumonia on chest x-ray or lung CT scan. The other inclusion criteria were either laboratory-confirmed SARS-CoV-2 or typical lung infiltrates on a lung CT scan, and either an oxygen saturation of 93% or less under oxygen 6 L/min or more, or aggravation (saturation ≤93% under oxygen 3 L/min) with a loss of 3% of oxygen saturation in ambient air over the previous 24 h. The historical control group of patients had the same inclusion criteria. Patients in the anakinra group were treated with subcutaneous anakinra (100 mg twice a day for 72 h, then 100 mg daily for 7 days) as well as the standard treatments at the institution at the time. Patients in the historical group received standard treatments and supportive care. The main outcome was a composite of either admission to the intensive care unit (ICU) for invasive mechanical ventilation or death. The main analysis was done on an intention-to-treat basis (including all patients in the anakinra group who received at least one injection of anakinra). FINDINGS: From March 24 to April 6, 2020, 52 consecutive patients were included in the anakinra group and 44 historical patients were identified in the Groupe Hospitalier Paris Saint-Joseph COVID cohort study. Admission to the ICU for invasive mechanical ventilation or death occurred in 13 (25%) patients in the anakinra group and 32 (73%) patients in the historical group (hazard ratio [HR] 0·22 [95% CI 0·11–0·41; p<0·0001). The treatment effect of anakinra remained significant in the multivariate analysis (HR 0·22 [95% CI 0·10–0·49]; p=0·0002). An increase in liver aminotransferases occurred in seven (13%) patients in the anakinra group and four (9%) patients in the historical group. INTERPRETATION: Anakinra reduced both need for invasive mechanical ventilation in the ICU and mortality among patients with severe forms of COVID-19, without serious side-effects. Confirmation of efficacy will require controlled trials. FUNDING: Groupe Hospitalier Paris Saint-Joseph.
has issue date	2020-05-29(xsd:dateTime)
bibo:doi	10.1016/s2665-9913(20)30164-8
bibo:pmid	32835245
has license	no-cc
sha1sum (hex)	3e01d1740656ce4504e2ff38527f02a628803fa8
schema:url	https://doi.org/10.1016/s2665-9913%2820%2930164-8
resource representing a document's title	Anakinra for severe forms of COVID-19: a cohort study
has PubMed Central identifier	PMC7259909
has PubMed identifier	32835245
schema:publication	Lancet Rheumatol
resource representing a document's body	covid:3e01d1740656ce4504e2ff38527f02a628803fa8#body_text
is schema:about of	named entity 'Background' named entity 'IL-1 receptor antagonist' named entity 'production' named entity 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity 'IL-1 RECEPTOR' named entity 'HOSPITAL' named entity 'COVID-19' named entity 'CYTOKINES' named entity 'RECEPTOR ANTAGONIST' named entity 'AUTOINFLAMMATORY DISORDERS' named entity 'CORONAVIRUSES' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2' covid:arg/3e01d1740656ce4504e2ff38527f02a628803fa8 named entity 'assess' named entity 'patients' named entity 'off-label' named entity 'interleukin' named entity 'anakinra' named entity 'cytokines' named entity 'interleukin' named entity 'Anakinra' named entity 'respiratory rate' named entity 'invasive mechanical ventilation' named entity 'nasal cannula' named entity 'oxygen therapy' named entity 'lung' named entity 'subcutaneous' named entity 'influenza-like' named entity 'invasive ventilation' named entity 'subcutaneously' named entity 'haemophagocytic lymphohistiocytosis' named entity 'absolute difference' named entity 'CRP' named entity 'haemo' named entity 'hydroxychloroquine' named entity 'IL-1β' named entity 'chimeric antigen receptor' named entity 'anakinra' named entity 'thromboembolic' named entity 'Chest CT' named entity 'medication error' named entity 'asthma' named entity 'fever' named entity 'lung' named entity 'pharmacokinetic profile' named entity 'sample size' named entity 'COVID' named entity 'C-reactive protein' named entity 'ethics committee' named entity 'bilateral pneumonia' named entity 'anakinra' named entity 'Swedish Orphan Biovitrum' named entity 'β-lactam antibiotics' named entity 'cytokine storm' named entity 'multiple organ dysfunction' named entity 'anakinra' named entity 'anakinra' named entity 'anakinra' named entity 'COVID-19' named entity 'aetiology' named entity 'tissue factor' named entity 'medical record'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software